arrow
T

Tanya B. Dorff

city of hope comprehensive cancer center
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG-1216 Phase 3 Trial

前列腺切除术后转移时间作为异时性mHSPC患者预后因素的评估:SWOG-1216 III期试验的二次分析

2026-10-070
OAAI
Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer

探索与转移性去势抵抗性前列腺癌患者从talazoparib单药治疗中获益延长或耐药相关的肿瘤基因组学研究

2026-09-290
OA
Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer

吸烟、肿瘤遗传学与转移性前列腺癌患者预后的关联

2026-09-050
PRE
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)

卡博替尼(XL184)联合纳武利尤单抗和伊匹木单抗治疗低分化神经内分泌癌的2期研究(ETCTN10315)

2026-04-100
OA
Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis

局部前列腺癌行根治性前列腺切除术的拉丁裔亚人群结局差异:一项基于人群的分析

Cancers
IF4.4
2026-04-030
OAAI
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel

前列腺癌的演变策略:来自“弥合前列腺癌差距”专家小组的 emerging approaches 和 unmet needs

Cancer
IF5.1
2026-02-110
OAAI
Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care

将PSMA靶向诊疗整合到多学科护理中以提高效率和患者护理

2025-12-011
PRE
Prostate Cancer, Version 3.2026

前列腺癌,版本3.2026,NCCN肿瘤学临床实践指南

2025-11-012
PRE
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617

PSMA阳性转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617治疗后的基因组改变及关联结局

2025-11-010
PRE
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy

Talazoparib单药治疗具有DNA损伤应答改变的转移性去势抵抗性前列腺癌——与治疗反应相关的基因组特征

2025-10-300
PRE
Real-World efficacy and safety of belzutifan in sporadic metastatic renal cell carcinoma: a multicenter study from the city of hope enterprise

belzutifan在散发性转移性肾细胞癌中的真实世界有效性与安全性:一项来自City of Hope Enterprise的多中心研究

2025-10-010
OAAI
Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer

在去势抵抗性前列腺癌患者中,使用恩扎卢胺单药或联合镭-223治疗期间的免疫调节

CANCERS
IF4.4
2025-05-210
OA